We are excited to announce that Eagle IP will be participating as a sponsor and exhibitor at the upcoming Life Sciences Patent Network (LSPN) North America Fall Conference in San Francisco. Our President and Managing Director, Ms. Jennifer Che, is a distinguished speaker at the event. Her talk, titled China Patent Landscape, will provide a brief overview of top China IP issues for life sciences companies and provide some strategies for how to navigate such issues (e.g., AI, post-filing data, PTA/PTE, patent linkage, export controls, and more).

Organized by Life Sciences Intellectual Property Review, this event will take place October 21-22, 2025.


Eagle IP will also be in the greater Washington DC area from October 27-31, 2025. Ms. Jennifer Che will be attending Life Sciences Masters™ 2025 (organized by IP Watchdog) in Ashburn, Virginia from October 27-29, and AIPLA 2025 Annual Meeting (organized by American Intellectual Property Law Association) in Washington DC from Oct 29-31.

If you won’t be able to attend LSPN or AIPLA, but will be in San Francisco or the Washington DC area and would like to schedule a meeting, please let us know. We look forward to seeing some of you in San Francisco and Washington DC later this month!

Our Past Events

Recommended Insights

China Hands Down First Batch of Patent Linkage “Paragraph IV” Litigation Results

30 June 2022
China has been implementing a plethora of new laws and measures that are particularly favorable to drug companies, such as patent term extension and patent linkage. Details of the new implementation measures for patent linkage (technically “early dispute resolution mechanisms for drug patents”) came into effect on July 4, 2021. At around the same time, […]

CHINA DIVISIONAL PATENT STRATEGY: Recent Judgment Narrows What Constitutes “Different Inventions” for Divisionals

6 December 2021
In China, patents applicants take advantage of a commonly-used divisional filing strategy to achieve a fine-tuned balance between protection scope and protection period (if used properly). Patent applicants (especially foreign applicants) widely welcome this well-established strategy, and up until now, have used it with much success. In fact, we recommend this strategy and have even […]

NMPA's Releases Draft Measures for Data Protection (Data Exclusivity)

4 September 2025
In March 2025, China's National Medical Products Administration (NMPA) released yet another set of draft implementation measures on data protection.1 Key highlights of these new measures include the following: A Bit of History China's journey toward a comprehensive pharmaceutical data protection framework has been ongoing for over two decades, a roller coaster ride from its […]

China Announcing More Proposed Amendments to the Examination Guidelines in 2022

17 November 2022
It’s been a year and a half since the new Chinese Patent Law came into effect (1 June 2021). Although various versions of draft Examination Guidelines have been released, thus far no official finalized versions have been confirmed. On October 31, 2022, yet another new list of proposed amendments was published1, this time consolidating the […]
Top crossarrow-right